environ 2500 décisions enregistrées en 2024
Summary of Recent Developments in Algeria’s Pharmaceutical Sector
Key Insights from the National Pharmaceutical Agency (ANPP)
In 2024, the National Agency of Pharmaceutical Products (ANPP) in Algeria reported significant advancements in the registration and approval processes for medicinal products and medical devices. The agency recorded approximately 2,500 decisions pertaining to these approvals, marking a substantial increase compared to previous years.
Detailed Breakdowns of Approvals and Registrations
According to Khadidja Bouguerra, the agency’s quality management head, around 1,350 medicinal product registrations and over 1,100 medical device approvals were completed last year. This represents a notable rise from 2023, where only about 1,050 decisions were made. The increase indicates an enhancement in ANPP’s operational efficiency and a transition to a more stable and transparent regulatory framework.
Local Production and Market Coverage
Bouguerra highlighted that domestic products now account for 79% of the market demand, which underscores the agency’s commitment to improving local production capabilities. The focus is on streamlining procedures while ensuring that quality and safety standards are not compromised. The agency employs thorough evaluations, including dossier studies, laboratory analyses, and scientific assessments, to achieve these goals.
Encouragement of Investments in the Pharmaceutical Sector
Bouguerra noted a growing interest from investors, attributing this to the effective regulatory environment established over the last four years. This shift aligns with the government’s vision to bolster investment in the pharmaceutical sector and enhance local production.
In line with directives from the Ministry of Pharmaceutical Industry, the ANPP is actively guiding investors toward the production of medicines that are in short supply within the market. Bouguerra expressed confidence in the local industry’s comprehensive understanding and capabilities across various medication categories.
Focus on Innovative and Biotechnological Drug Production
The agency is also steering operators towards investments in innovative medicines and biotechnology, aligning with global trends and advancements. This strategic direction aims to not only address existing market gaps but to position Algeria favorably in the dynamic global pharmaceutical landscape.
In conclusion, the ANPP’s efforts in enhancing the pharmaceutical regulatory framework and encouraging local production are critical for meeting market needs and fostering an environment conducive to innovation and investment. These developments are instrumental in ensuring the long-term sustainability of Algeria’s healthcare sector.
